Vivasure Medical

Executive Summary

Vivasure Medical is an Irish medical device company specializing in a fully bioabsorbable, sutureless patch-based closure system for large-bore vessel access. Founded in 2010 and headquartered in Galway, the company developed a novel technology that closes vascular puncture sites after procedures such as TAVR and EVAR, reducing complications and simplifying the closure process. In January 2026, Vivasure was acquired by Haemonetics Corporation, a global healthcare company focused on blood management and medical devices. This acquisition provides Vivasure with significant commercial resources and a global distribution network. The company's patented patch technology is designed to address the growing need for effective closure of large-bore access sites, driven by the increasing adoption of minimally invasive cardiovascular procedures. With Haemonetics' support, Vivasure is poised to accelerate regulatory clearances and market penetration, targeting both U.S. and international markets. Key milestones include potential expanded FDA approvals and clinical evidence generation to support broader adoption in interventional cardiology and vascular surgery.

Upcoming Catalysts (preview)

• Q4 2026FDA approval for expanded sheath size indication80% success
• H1 2027Commercial launch in European Union following Haemonetics integration70% success
• Q3 2026Publication of pivotal clinical trial results for next-generation patch75% success